Favorable outcomes of autoimmune hepatitis in a community clinic setting

Journal of Gastroenterology and Hepatology (Australia)

Volumn 23, Issue 9, 2008, Pages 1410-1414

  Seo, Suk ^a   Toutounjian, Raphael ^b   Conrad, Andrew ^c   Blatt, Larry ^d   Tong, Myron J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HUNTINGTON MEDICAL RESEARCH INSTITUTES   (United States)

^c National Genetics Institute   (United States)

^d InterMune Inc   (United States)

Author keywords

Autoantibodies; Autoimmune hepatitis; Hepatocellular carcinoma; Immunosuppression; Predictors; Prognosis; Treatment

Indexed keywords

ANTINUCLEAR ANTIBODY; AZATHIOPRINE; LIVER ANTIGEN; MICROSOME ANTIBODY; MITOCHONDRION ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; SMOOTH MUSCLE ANTIBODY;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; CHILD; CLINICAL FEATURE; DRUG DOSE REDUCTION; FEMALE; HEALTH CENTER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; VIRUS HEPATITIS;

EID: 49849097120     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2008.05365.x     Document Type: Article

References (28)

1. Czaja A. Autoimmune liver disease. Curr. Opin. Gastroenterol. 2003 19 : 232 42.
2. Alvarez F, Berg P, Bianchi F. International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis. J. Hepatol. 1999 31 : 929.
3. Homberg J, Abuaf N, Bernard O. Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1. A second type of 'autoimmune' hepatitis. Hepatology 1987 7 : 1333.
4. Kanzler S, Weidemann C, Gerken G. Clinical significance of autoantibodies to soluble liver antigen in autoimmune hepatitis. Hepatology 1999 31 : 635 40.
5. Czaja A, Carpenter H, Manns M. Antibodies to soluble liver antigen, P450IID6, and mitochondrial complexes in chronic hepatitis. Gastroenterology 1993 105 : 1522 8.
6. Davalos M, Roman R, Bustios C. Autoimmune hepatitis: clinical forms and related factors to their response to treatment. Rev. Gastroenterol. Peru 2004 24 : 305 13.
7. Van Leeuwen D, Sood G, Ferrante D. A 38-year-old African-American woman with an unusually rapid progression of 'Primary Biliary Cirrhosis': a missed opportunity!. Semin. Liver Dis. 2002 22 : 395 406.
8. Targan S, Landers C, Vidrich A et al. High-titer antineutrophil cytoplasmic antibodies in type 1 autoimmune hepatitis. Gastroenterology 1995 108 : 1159.
9. Czaja A, Davis G, Ludwig J et al. Autoimmune features as determinants of prognosis in steroid-treated chronic active hepatitis of uncertain etiology. Gastroenterology 1983 85 : 713 17.
10. Pavic S, Simonovic J, Boricic I et al. Autoantibodies characteristic for autoimmune hepatitis found in chronic hepatitis C. Srp. Arh. Celok Lek. 2003 131 : 437 42.
11. Soloway R, Summerskill W, Baggenstoss A. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 1972 63 : 820.
12. Czaja A, Davis G, Ludwig J et al. Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis. Hepatology 1984 4 : 622 7.
13. Dalekos G, Zachou K, Liaskos C. Autoantibodies and defined target autoantigens in autoimmune hepatitis: an overview. Eur. J. Intern. Med. 2002 13 : 293 303.
14. Strassburg C, Manns M. Autoantibodies and autoantigens in autoimmune hepatitis. Semin. Liver Dis. 2002 22 : 339 51.
15. Czaja A. Behaviour and significance of autoantibodies in type 1 autoimmune hepatitis. J. Hepatol. 1999 30 : 394 401.
16. Czaja A, Beaver S, Shiels M. Sustained remission after corticosteroid therapy of severe hepatitis B surface antigen-negative chronic active hepatitis. Gastroenterology 1987 92 : 215 19.
17. Czaja A, Ammon H, Summerskill W. Clinical features and prognosis of severe chronic active liver disease (CALD) after corticosteroid-induced remission. Gastroenterology 1980 78 : 518 23.
18. Czaja A, Ludwig J, Baggenstoss A et al. Corticosteroid-treated chronic active hepatitis in remission: uncertain prognosis of chronic persistent hepatitis. N. Engl. J. Med. 1981 304 : 5 9.
19. Hegarty J, Nouri Aria K, Portmann B et al. Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis. Hepatology 1983 3 : 685 9.
20. Davis G, Czaja A. Immediate and long-term results of corticosteroid therapy for severe idiopathic chronic active hepatitis. In : Czaja A, Dickson E, eds. Chronic Active Hepatitis, The Mayo Clinic Experience. New York : Marcel Dekker, Inc., 1986 269.
21. Czaja A, Menon K, Carpenter H. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. Hepatology 2002 35 : 890 7.
22. Roberts S, Therneau T, Czaja A. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology 1996 110 : 848.
23. Czaja A, Carpenter H. Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. Hepatology 2006 43 : 532 8.
24. Czaja AJ, Carpenter HA, Santrach PJ et al. Significance of HLA DR4 in type 1 autoimmune hepatitis. Gastroenterology 1993 105 : 1502 7.
25. Czaja AJ, Strettell MDJ, Thomson LJ et al. Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. Hepatology 1997 25 : 317 23.
26. Donaldson PT, Doherty DG, Hayllar KM et al. Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors. Hepatology 1991 13 : 701 6.
27. Seki T, Kiyosawa K, Inoko H et al. Association of autoimmune hepatitis with HLA-Bw54 and DR4 in Japanese patients. Hepatology 1990 12 : 1300 4.
28. Seki T, Ota M, Furuta S et al. HLA class II molecules and autoimmune hepatitis susceptibility in Japanese patients. Gastroenterology 1992 103 : 1041 7.